Potassium citrate (1080mg) is an oral alkalinizing agent and potassium supplement. Each 1080mg tablet provides approximately 10 mEq (milliequivalents) of potassium. It is primarily used to manage and prevent calcium oxalate and uric acid kidney stones by increasing urinary pH and citrate levels, and to treat or prevent hypokalemia in the context of metabolic acidosis. In the Indian context, it is a critical medication for recurrent nephrolithiasis, especially in regions with high prevalence of stone disease.
Adult: For stone prevention: 1080mg (10 mEq) two to three times daily with meals or within 30 minutes after meals. For hypokalemia: 1080mg two to four times daily. Dose MUST be individualized based on 24-hour urinary citrate, urinary pH, and serum potassium. Typical total daily dose: 2160mg to 6480mg (20-60 mEq).
Note: Take with a full glass of water (at least 240 mL) with food or immediately after a meal to minimize GI irritation. Swallow whole; do NOT crush, chew, or suck the tablet (can cause local ulceration). Do NOT lie down for at least 30 minutes after taking.
Potassium citrate exerts a dual mechanism: 1) Alkalinization: Following absorption, citrate is metabolized to bicarbonate, increasing systemic and urinary pH. A higher urinary pH (typically targeted to 6.0-7.0) increases the solubility of uric acid and cystine, preventing stone formation. It also inhibits the crystallization of calcium oxalate by forming soluble complexes with calcium. 2) Potassium Replenishment: It provides potassium ions to correct or prevent hypokalemia. Hypokalemia itself can cause hypocitraturia (low urinary citrate), a major risk factor for stones; thus, correction aids in stone prevention.
Pregnancy: Category C (US FDA). Use only if clearly needed. Animal studies are inconclusive. Benefits may outweigh risks in pregnant women with renal tubular acidosis or recurrent stones. Monitor electrolytes closely.
Driving: No effect on ability to drive or operate machinery. However, severe hyperkalemia can cause muscle weakness, which could be hazardous.
| ACE Inhibitors (e.g., Ramipril, Enalapril) | Increased risk of severe hyperkalemia due to reduced aldosterone. | Major |
| Angiotensin II Receptor Blockers (ARBs e.g., Telmisartan, Losartan) | Increased risk of severe hyperkalemia due to reduced aldosterone. | Major |
| Potassium-Sparing Diuretics (e.g., Spironolactone, Amiloride) | Additive hyperkalemic effect. | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | May reduce renal potassium excretion, increasing hyperkalemia risk. | Moderate |
| Heparin (including LMWH) | Can inhibit aldosterone, increasing hyperkalemia risk. | Moderate |
| Digoxin | Hyperkalemia can potentiate digoxin toxicity. Hypokalemia (if patient stops citrate) increases digoxin toxicity risk. | Moderate |
| Anticholinergics (e.g., Dicyclomine) | May slow GI transit, increasing risk of GI mucosal injury from tablet. | Minor |
Same composition (Potassium Citrate (1080mg)), different brands: